cardiovascular,diabetes

GSK1940029 (SCD inhibitor 1) is an inhibitor of stearoyl-CoA desaturase (SCD).

CP-642931 (Sorbitol dehydrogenase-IN-1) is an orally active and highly potent sorbitol dehydrogenase inhibitor for the study of diabetes and cardiovascular disease.

GPR35 agonist 3 is a synthetic GPR35 agonist with an EC50 value of 1.4 μg in the β-arrestin recruitment assay.GPR35 agonist 3 is used in the study of cancer, type 2 diabetes, and cardiovascular disease.

AICAR (Acadesine) is an AMPK activator. AICAR has the functions of metabolic regulation, muscle function regulation, anti-cancer effect, neuroprotection and anti-aging.

Bisphenol A is an endogenous metabolic compound of phenols and is widely used in the production of epoxy resins and polycarbonate plastics. It is reproductive, developmental and systemic toxicant and is often classified as an endocrine disruptor. It has been linked to many diseases, including respiratory disease, cardiovascular disease, diabetes, kidney disease, obesity and reproductive disorders.

NSC-6038 (4-chloro-N,N-dipropylbenzamide) is a benzamide-based bioactive compound with a wide range of biological activities and has been shown to possess anti-inflammatory, antioxidant and anti-angiogenic activities, and has also been shown to be effective in the treatment of a wide range of diseases such as cancer, diabetes and cardiovascular diseases.

Sirtuin modulator 2 (N-(3-(imidazo[2,1-b]thiazol-6-yl)phenyl)-2-methoxybenzamide) exhibits antidiabetic, anti-inflammatory and antitumor activities.

Semaglutide TFA is a glucagon-like peptide-1 congener that induces weight loss, lowers blood glucose levels, and reduces cardiovascular risk in diabetic patients.Semaglutide TFA induces mild-to-moderate and transient gastrointestinal disturbances, and may be used in the study of type 2 diabetes and obesity.

TXNIP-IN-1 is an inhibitor of the TXNIP-TRX complex and used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease.

DGAT2-IN-3 (compound 9) is an inhibitor of DGAT2 with an IC50 value of 0.4 nM. It is utilized in research related to fatty liver disease, diabetes, and cardiovascular diseases.

Haptoglobin, Phenotype 2-2 is a plasma protein that binds hemoglobin (Hb) to remove free hemoglobin and possesses antioxidant activity. It can be utilized in research related to kidney failure and cardiovascular diseases associated with diabetes.

AMPK activator17 (Compound 10g) is an orally bioavailable AMPK activator. It significantly inhibits lipogenesis (IC50: 3.4 μM) and improves dyslipidemia. By activating the AMPK pathway, AMPK activator17 suppresses early adipocyte differentiation (mitotic clonal expansion) and enhances mitochondrial function and fatty acid oxidation in mature adipocytes. It improves dyslipidemia through promoting cholesterol reverse transport. AMPK activator17 is applicable in research on obesity and associated metabolic disorders, such as type 2 diabetes and cardiovascular diseases.

Neuromedin U (NMU) is a neuropeptide first demonstrated to drive smooth muscle contraction.1Translated as a 174 amino acid propeptide, NMU is cleaved to different lengths in different animals. It has diverse receptor-mediated rolesin vivo, as it regulates feeding, vasoconstriction, nociception, and bone remodeling and contributes to obesity, cancer and septic shock.2,2NMU-25 is the active form of NMU in humans. It binds with high affinity to receptors on human left ventricle and coronary artery (KDs = 0.26 and 0.11 nM, respectively), eliciting endothelium-independent vasoconstriction.3NMU-25 also suppresses glucose-stimulated insulin secretion in human islets, and this effect is lost in NMU R165W mutants, resulting in early-onset obesity.4 1.Mitchell, J.D., Maguire, J.J., and Davenport, A.P.Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin SBritish Journal of Pharmacology15887-103(2009) 2.Greenwood, H.C., Bloom, S.R., and Murphy, K.G.Peptides and their potential role in the treatment of diabetes and obesityRev.Diabet.Stud.8(3)355-368(2011) 3.Mitchell, J.D., Maguire, J.J., Kuc, R.E., et al.Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular systemCardiovascular Research81353-361(2009) 4.Alfa, R.W., Park, S., Skelly, K.R., et al.Suppression of insulin production and secretion by a decretin hormoneCell Metabolism21(2)323-333(2015)

BTK-IN-5, a covalent inhibitor of Bruton's tyrosine kinase (BTK), is designed for treating cardiovascular diseases, respiratory diseases, inflammation, and diabetes.

Benzamide, 3-methoxy-N-(3-thiazolo[5,4-b]pyridin-2-ylphenyl) (3-methoxy-N-(3-(thiazolo[5,4-b]pyridin-2-yl)phenyl)benzamide) is a sirtuin modulator and useful for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including diabetes, cardiovascular disease, bloo

Sirtuin Modulator 4, a sirtuin modulator, exhibits an inhibitory effect on SIRT1, presenting an EC 50 value ranging from 51-100 μM. It is potentially useful in research aimed at prolonging cell lifespan and preventing a broad spectrum of diseases and disorders such as diabetes, obesity, neurodegenerative, cardiovascular diseases, inflammation, and cancer.

Lipoprotein lipase (LPL) is an enzyme, mainly involved in lipid metabolism, that hydrolyzes triglycerides in lipoproteins.LPL can be a target for obesity/diabetes-related cardiovascular diseases and has an important role in lowering triglyceride levels and improving cardiovascular.

Sirtuin Modulator 5, a sirtuin modulating agent, activates SIRT1 with an efficacy marked by a DC50 value of less than 50 μM. It is applicable in enhancing cell longevity and is researched for its therapeutic potential in a wide range of diseases such as those associated with aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular diseases, blood clotting disorders, inflammation, cancer, and flushing. Furthermore, it holds promise for conditions that could benefit from boosted mitochondrial activity [1].

Gevokizumab (S-78989) is a humanised monoclonal antibody targeting IL-1β, which blocks IL-1β signalling through allosteric regulation, and can be used for diabetes, cancer, inflammation, and cardiovascular diseases.

WAY-339495 may have anti-tumor, anti-inflammatory and analgesic activity and can be used to study obesity, cardiovascular disease, diabetes, neurodegenerative diseases, Alzheimer's disease and stroke.

2-Hydroxyflavanone is a naturally occurring flavonoid found in many plants and fruits. It has antioxidant, anti-inflammatory and anti-tumor activity, scavenging free radicals, reducing inflammation and inhibiting the growth of tumor cells. It also has the potential to treat a wide range of diseases including diabetes, obesity, cardiovascular disease and neurological disorders.

sEH-IN-1 (example 67), an inhibitor of soluble epoxide hydrolase (sEH), is utilized in studying diseases mediated by sEH, including hypertension, cardiovascular disease, inflammation, and diabetes [1].

SHLP-1 is a mitochondria-derived peptide encoded by the MT-RNR2 gene, a biologically active microprotein derived from 16S ribosomal RNA (MT-RNR2). This compound is utilized in research related to diabetes, Alzheimers disease, cardiovascular diseases, and prostate cancer.

3-Hydroxypalmitoylcarnitine (Standard) is an acylcarnitine involved in fatty acid metabolism processes, which has been associated with type 2 diabetes and cardiovascular disease. As a standard, it can be used for quantitative analysis, study of metabolic pathways and diagnosis of related diseases.